GRO1 inhibitors are a distinct class of chemical compounds that function by targeting and inhibiting the activity of the Growth-regulated oncogene 1 (GRO1) protein. GRO1, also known as CXCL1, is a chemokine involved in various cellular processes including cell proliferation, migration, and angiogenesis. The inhibition of GRO1 can result in the modulation of signaling pathways that regulate these fundamental cellular activities. GRO1 inhibitors typically achieve this by binding to the GRO1 protein or its receptor, CXCR2, thereby blocking the interaction and subsequent downstream signaling cascades. This blockade can alter the expression of various genes and proteins involved in the regulation of the cell cycle, apoptosis, and other cellular mechanisms.
In the realm of biochemical research, GRO1 inhibitors are instrumental in elucidating the underlying mechanisms of GRO1-related cellular processes. They serve as crucial tools in studying the regulatory networks influenced by GRO1 and its associated signaling pathways. By modulating GRO1 activity, researchers can gain insights into the protein's role in cellular dynamics and its broader implications in tissue homeostasis and pathology. Moreover, GRO1 inhibitors are often employed in various experimental models to investigate the effects of GRO1 inhibition on cell behavior, including changes in gene expression profiles, alterations in cellular morphology, and impacts on cell-cell communication. Through such studies, GRO1 inhibitors contribute significantly to our understanding of the molecular basis of cellular functions and the intricate web of signaling pathways governing these processes.
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Reparixin | 266359-83-5 | sc-507446 | 5 mg | $76.00 | ||
レパリキシンは、CXCL1の主要受容体であるCXCR1を標的とする低分子アンタゴニストです。CXCL1誘発性の炎症および好中球の動員に対する阻害効果が示されています。 | ||||||
AZD 5069 | 878385-84-3 | sc-507447 | 5 mg | $230.00 | ||
AZD5069は、CXCR1の選択的阻害剤です。CXCL1を介した好中球の遊走を阻害する効果を示しており、炎症性肺疾患の治療薬として研究されています。 | ||||||
SB 225002 | 182498-32-4 | sc-202803 sc-202803A | 1 mg 5 mg | $35.00 $100.00 | 2 | |
SB225002は、CXCRIを標的とする低分子アンタゴニストであり、CXCL1によって誘導される好中球の活性化と遊走を阻害する効果を示した。 | ||||||